Lung Cancer in Patients of African Descent: A Transcontinental Review of Epidemiology, Disparities, Outcomes, and Opportunities for Equity in Africa, North America, South America, and the Caribbean [0.03%]
非洲血统患者的肺癌：泛大陆回顾——流行病学、差异性、结局及在非洲、北美洲、南美洲和加勒比地区实现公平的机会
Elvis Obomanu,Colton Jones,Verna Vanderpuye et al.
Elvis Obomanu et al.
Lung cancer in people of African descent is characterized by transcontinental disparities driven by epidemiologic heterogeneity, systemic inequities, and unequal access to health care. Globally, lung cancer incidence and mortality rates var...
Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study [0.03%]
一项局部消融治疗后再次使用奥希替尼治疗寡进展性EGFR突变型NSCLC患者的II期研究
Azam Ghafoor,Nitin Roper,Chul Kim et al.
Azam Ghafoor et al.
Introduction: Osimertinib has exhibited impressive efficacy in advanced EGFR-mutated NSCLC; however, resistance is inevitable. We hypothesized that local ablative therapy (LAT) for oligoprogressive disease (up to five sit...
Predictive Factors for Smoking Cessation Among People With Lung Cancer Attending French Cessation Services, According to Sex [0.03%]
法国戒烟门诊中肺癌患者的性别差异预测了其戒烟效果的影响因素分析
Anne-Laurence Le Faou,Dalia Alleaume,Ingrid Allagbé
Anne-Laurence Le Faou
Background: Limited research exists on sex-specific smoking cessation interventions for patients with lung cancer. This study leverages data from the Consultations de Dépendance Tabagique, the French national database of...
Shedding Phosphorylated Axl Receptor in Lung Adenocarcinoma: Dual-Domain Immunohistochemistry Approach [0.03%]
肺癌肺腺癌中Axl受体磷酸化脱落：双重结构域免疫组化方法研究
Shuji Mishima,Takashi Eguchi,Yoshinori Sato et al.
Shuji Mishima et al.
Introduction: Axl, a receptor tyrosine kinase, is linked to epithelial-mesenchymal transition (EMT). This study aimed to investigate the biologic implications of extracellular domain shedding of phosphorylated Axl (pAxl) ...
First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup Analysis [0.03%]
LIBRETTO-431试验的亚组分析：东亚RET融合阳性NSCLC患者的塞普替尼与化疗联合帕博利珠单抗的一线治疗比较
Koichi Goto,Herbert H Loong,Caicun Zhou et al.
Koichi Goto et al.
Introduction: Selpercatinib's consistent efficacy and manageable safety profile were observed in patients with RET fusion-positive NSCLC across geographies in single-arm studies (LIBRETTO-001 and LIBRETTO-321). Here, we r...
Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC [0.03%]
meta分析探索受体酪氨酸激酶抑制剂诱导的基因成瘾非小细胞肺癌患者的体重增加
Ilaria Mariangela Scaglione,Alice Avancini,Serena Eccher et al.
Ilaria Mariangela Scaglione et al.
Background: For patients with oncogene-addicted NSCLC treated with tyrosine kinase inhibitors (TKIs), weight gain has recently gained attention as a frequent treatment-related effect. Identifying those TKIs more frequentl...
Complete Response to BET Inhibitor in Primary Pulmonary NUT Carcinoma With Single-Cell Sequencing-Based Analysis: A Case Report [0.03%]
基于单细胞测序的BET抑制剂治疗原发性肺NUT癌完全缓解的一例报告
Zhuomiao Ye,Xin Li,Minghui Zhang et al.
Zhuomiao Ye et al.
NUT carcinoma is a rare and highly aggressive malignancy characterized by rapid progression, resistance to conventional therapies, and an extremely poor prognosis. This report presents a 36-year-old patient with stage IIIB primary pulmonary...
Older Adult Participation in Early-Phase Lung Cancer Clinical Trials, 1998 to 2020 [0.03%]
1998年至2020年早期肺癌临床试验中老年患者的参与情况
Desirae Ehley,Lilit Vardanyan,Rebecca S Boxer et al.
Desirae Ehley et al.
Objectives: Despite advances, lung cancer treatment remains associated with substantial toxicity. Early-phase clinical trials inform the safety and efficacy of novel lung cancer treatments. Although older adults represent...
Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish Cohort [0.03%]
对KRAS突变型而非野生型转移性肺腺癌患者进行免疫检查点单药治疗可改善生存结果：来自瑞典扩大队列的验证研究
Ella A Eklund,Sama I Sayin,Jonas Smith Jonsson et al.
Ella A Eklund et al.
Introduction: Immune checkpoint blockade (ICB) is a standard first-line treatment for stage IV NSCLC without actionable oncogenic alterations. KRAS mutations, prevalent in 30% to 40% lung adenocarcinomas (LUAD) in Western...
Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response [0.03%]
简报：一项前瞻性试验评估了派姆单抗在转移性NSCLC中的单药治疗效果，并将循环肿瘤DNA作为反应的替代生物标志物进行评价
Iris van &#x;t Erve,Isabelle Blanchard,Judy Y Pagtama et al.
Iris van &#x;t Erve et al.
Immune checkpoint inhibitors provide clinical benefit to a subset of patients with metastatic NSCLC, yet the reliable prediction of long-term outcomes remains challenging. We conducted a prospective phase 2 clinical trial to evaluate circul...